Ondine Biomedical H1 revenue rises 23% on new hospital deployments

Canada’s life sciences firm said H1 revenue increased 23% year-on-year, driven by new hospital deployments and higher utilisation. Operating loss widened due to higher R&D spend for its LANTERN Phase 3 trial; sales and marketing expenses were held flat.